36 results about "Nicorandil" patented technology

Disclosed is a process for the synthesis of Nicorandil (1), 2-(nicotinamide)ethyl nitrate, starting from N-(2-hydroxyethyl)nicotinamide (15), using nitration with nitric acid in the presence of acetic anhydride Said synthesis method is particularly advantageous because it solves the safety problems involved in the use of nitric acid as nitrating agent, and allows a product with excellent yields and quality to be isolated.

The invention relates to a stable freeze-drying nicorandil powder injection and a preparation method thereof. In the process of preparing the freeze-drying nicorandil powder injection, acidifying or alkalizing agent is adopted to regulate the pH value of intermediate solution for the pH value to range from 5.0 to 8.0, and secondary sublimation temperature is controlled in the process of freeze drying for the temperature to range from 5 DEG C to 20 DEG C, and thereby, the medicament content and the stability of related substances are improved. The invention overcomes the deficiencies in the prior art; and a stable freeze-drying nicorandil powder is obtained, and the freeze-drying powder injection has good clinical efficacy.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to an HPLC analytic method for Nicorandil-related substances. The HPLC analytic method is characterized in that a stationary phase is a reversed-phase column of carbon octadecyl silane, and a moving phase is a mixed solution of a buffer solution, methyl alcohol and tetrahydrofuran. The HPLC analytic method is quick, simple and accurate, is good in repeatability and suitable for control and stability study of the related substances, lays a foundation for formulating quality standards of the related substances, and makes drug quality control and medication safety possible. Through scaling down organic solvents and volatile salt, which have high toxicity, the acquisition time is shortened, the economic cost is lowered, the HPLC analytic method is suitable for large-scale production, and meanwhile, harms to experimenters and environments are reduced.

The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to stimulate mitochondrial function in cells. The methods and compositions described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia /reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.

A pharmaceutical composition containing nicorandil, mannitol, and the alkali metal salt of an organic carboxylic acid, wherein (1) "the peak value of the delta crystals of mannitol at 9.8 DEG +-0.3 DEG (2[theta]) in X-ray diffraction "/"the peak value of nicorandil crystals at 10.6 DEG +-0.3 DEG (2[theta]) in X-ray diffraction" is 2.0 or less or (2) "the peak intensity at 1.01 THz +-0.2 THz of the secondary derivative spectrum in the absorption spectrum of the delta crystals of mannitol measured by means of terahertz transmission spectroscopy"/" the peak intensity at 0.95 THz +-0.2 THz of the secondary derivative spectrum in the absorption spectrum of nicorandil crystals measured by means of terahertz transmission spectroscopy" is 1.5 or less. This pharmaceutical composition exhibits excellent storage stability.

The invention discloses a process for preparing Nicorandil freeze-dried powder, which consists of charging 0.1-50.0 wt% of Nicorandil into water for injection, dissolving excipient simultaneously, degerming and filtering, loading, and finally freeze drying.

The invention discloses a process for preparing Nicorandil tablets through charging diluent, binding agent, crumbling agent, lubricating agent, flow adjuvant and anti-oxidizing agent into 0.5-25.0 wt% of Nicorandil. The tablets can be prepared through direct powder pelleting method, dry method granulation pelleting or blank granulation method.

The invention provides a method for preparing a nicorandil tripolymer. The method comprises the following steps: (1) dissolving nicorandil into an organic solvent, stirring and reacting for 4-7 hours;(2) slowly dropping a crystallization solvent into the reaction solution after the reaction is ended, slowly cooling to a room temperature, stirring and crystallizing, filtering to obtain a crude product, and washing with an organic solvent; and (3) adding the crude product into a re-crystallization solvent, and re-crystallizing, thereby obtaining the solid nicorandil tripolymer nitrate. According to the method for preparing the nicorandil tripolymer disclosed by the invention, the nicorandil tripolymer can be conveniently and rapidly prepared, and the prepared nicorandil tripolymer is high in yield and excellent in purity.

The invention relates to a method of measuring related substances in nicorandil tablets by HPLC (high performance liquid chromatography) correction factor process. The method performs measuring according to specifications in high performance liquid chromatography set forth in the general principle 0512 of Chinese Pharmacopoeia 2015 edition volume IV; C18 chromatographic column is used, trifluoroacetic acid-triethylamine-tetrahydrofuran-water mixed solution is used as a mobile phase to carry out measuring; impurities that may be quantitatively measured include impurity A, impurity B, impurity C, impurity D, impurity E and related known substances; the method has good methodological properties, such as wide linear range of test, good linearity, small detection limit and quantification, and good precision.

The invention provides a eutectic crystal of nicorandil and salicylic acid as well as a preparation method and application of the eutectic crystal. According to the invention, the eutectic crystal ofnicorandil and salicylic acid is comprehensively characterized by using analysis means such as X-ray diffraction analysis, thermogravimetric analysis, differential scanning calorimetry analysis, infrared spectroscopy and the like. Through stability test and comparison, the eutectic crystal has more excellent damp-heat stability compared with a nicorandil active pharmaceutical ingredient, and the safety, effectiveness and quality controllability of the medicine are improved.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of nikkodil. The preparation method includes: performing a reaction on nitric acidwith N-(2-hydroxyethyl) nicotinamide under the action of a dehydrating agent and a diluent to prepare N-(2-hydroxyethyl) nicotinamide nitrate, wherein the molar ratio of the N-(2-hydroxyethyl) nicotinamide to the nitric acid to the dehydrating agent is 1 : (2-3) : (1-2), and the volume-weight ratio of the diluent to the N-(2-hydroxyethyl) nicotinamide is (5-20) : 1. According to the preparation method of the nikkodil, the reaction process is mild and controllable, the preparation risk is low, the heat release is not obvious, a large amount of acid water is not generated, the safety problem issolved, and the environmental protection pressure is reduced; and the prepared product is high in purity and excellent in quality.

The present invention provides a composition comprising (i) Nicorandil, and (ii) a lubricant selected from a saturated higher aliphatic acid and its salts and/or a saturated higher alcohol, which is solid at ambient temperature, wherein the lubricant is not micronized; processes for preparing such composition; processes for preparing tablets from such composition; and tablets prepared by such processes.

The invention discloses an anti-angina pharmaceutical composition containing nicorandil. The anti-angina pharmaceutical composition comprises the nicorandil, beta receptor blocker and pharmaceutically acceptable excipients. The pharmaceutical composition has the advantages that the pharmaceutical composition has good angina and myocardial ischemia resisting effects, drug resistance cannot be caused easily, various adverse reactions of single medicine use can be overcome, toxic and side effects are lowered, and the pharmaceutical composition shows good synergistic effect in angina resisting and the treatment of myocardial ischemia.

The invention relates to a preparation method of nicorandil for injection. The nicorandil for injection, disclosed by the invention, is prepared from nicorandil, mannitol, sodium citrate and water for injection through the procedures of liquid preparation and freeze drying, and the weight ratio of all the components is as follows: nicorandil: mannitol: sodium citrate: water for injection is 2: 3: 1: (300-600). The preparation method of the nicorandil for injection, disclosed by the invention, comprises the following steps: step 1, liquid preparation, and step 2, freeze-drying, wherein the freeze-drying step further comprises the following steps: step A, pre-freezing, freeze-thawing, crystallizing and annealing, and step B, sublimation stage.

An embodiment of the invention provides a Nicorandil lipid microsphere preparation and a preparation method thereof and relates to the field of drug dosage forms, aiming to solve the technical problemthat an existing Nicorandil dosage form is not high in stability. The Nicorandil lipid microsphere preparation comprises Nicorandil, oil for injection, an emulsifier and water for injection, whereinthe Nicorandi is wrapped in the oil for injection in the size of 10-900nm, and the oil for injection is dispersed in the water for injection.

Disclosed herein are pyridyl compounds. Also described are specific conjugated nicorandil compounds. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the pyridyl compounds are disclosed for the treatment of diseases or conditions related to kidney or kidney functions.

The invention relates to a slow-release agent of Nicotie and relative production, wherein it uses Nicotie as material, adds slow-release skeleton material and drug to obtain solid disperser; releases the drug to hold blood density. The invention can reduce feeding time, reduce blood peak-valley condition, improve safety and reduce drug consumption.

The present invention utilizes ultramicropulverization and dripping pill preparation production process to make nicorandil dripping pills, and can attain the goal of raising disintegration and dissolution speed, quickly obtaining therapeutic effect, raising production cost and convenient administration. Said pill not only can be sucked, but also can be swallowed, and its compliance property is good.

The invention discloses a preparation method of Nicorandil, the preparation method comprises the following steps: directly synthesizing N-(2-ethoxyl) nicotinamide by taking nicotinamide as an initial raw material through a transamidation method, and nitrifying by using a mixture of non-fuming nitric acid, acetic anhydride and concentrated sulfuric acid to obtain Nicorandil. The method simplifies the existing synthesis process, is easy and convenient to operate and is more suitable for large-scale production; meanwhile, the yield of products obtained in each step of reaction is increased, the types and the dosage of reaction reagents are greatly reduced, and the production cost is lower. The technical problems of more reaction steps, high reagent consumption, low production efficiency, serious environmental pollution, poor quality of the prepared product and low yield of the existing preparation process are solved.

The invention discloses a method for determining the content of phorone in Nicodil by gas chromatography-mass spectrometry, which comprises the following steps of: 1, preparing a reference substance solution, precisely weighing a phorone reference substance, putting the phorone reference substance into a volumetric flask, dissolving the phorone reference substance to a scale by using a diluent, and uniformly shaking; 2, preparing a test solution, precisely weighing a dinitrandil raw material medicine, putting the dinitrandil raw material medicine into a volumetric flask, dissolving the dinitrandil raw material medicine to a scale by using a diluent, and uniformly shaking; 3, taking the diluent as a blank sample, and placing the diluent in a volumetric flask; and 4, precisely measuring the test solution and the reference solution, performing sample introduction, performing separation analysis by adopting a gas chromatograph-mass spectrometer, and recording a spectrogram. The detection method provided by the invention is verified by a test, and a result shows that the method is strong in specificity, good in precision and high in accuracy, and can be used for rapidly determining the content of the phorone in the Nicodil.

The invention relates to a eutectic crystal of nicorandil and 1-hydroxy-2-naphthoic acid, and a preparation method and application thereof. The eutectic crystal of the nicorandil and the 1-hydroxy-2-naphthoic acid is comprehensively characterized by applying analysis means such as X-ray diffraction analysis, thermogravimetric analysis, differential scanning calorimetry analysis, infrared spectroscopy and the like. Through stability test and comparison, the eutectic crystal has more excellent damp-heat stability compared with a nicorandil raw material medicine, and the safety, effectiveness andquality controllability of the medicine are improved.